Lindbrook Capital, LLC Chemo Centryx, Inc. Transaction History

Lindbrook Capital, LLC

$1.18 Billion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 10, 2022	BUY	$22.17 - $51.8 $2,571 - $6,008	116 Added 91.34%	243 $13,000
Q2 2022 Aug 01, 2022	BUY	$15.36 - $27.51 $1,059 - $1,898	69 Added 118.97%	127 $3,000
Q1 2022 Apr 21, 2022	BUY	$22.22 - $39.12 $488 - $860	22 Added 61.11%	58 $1,000
Q3 2021 Nov 05, 2021	BUY	$13.18 - $19.83 $474 - $713	36 New	36 $1,000
Q2 2019 Jul 24, 2019	SELL	$8.31 - $14.85 $6,232 - $11,137	-750 Closed	0 $0
Q1 2019 Apr 23, 2019	BUY	$10.01 - $13.89 $7,507 - $10,417	750 New	750 $10,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.